Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has received feedback from the US FDA following its 'end of review' Type A meeting request with respect to the Sofdra new drug application review. …
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 29 August
August 29, 2025 - - Podcast -
Government pressed on diabetes inquiry response as obesity costs soar
August 29, 2025 - - Latest News -
NDIS quarterly report presents a positive picture, but questions remain
August 29, 2025 - - Latest News -
Wesfarmers Health delivers growth as Priceline drives consumer momentum
August 29, 2025 - - Latest News -
'We can evade reality, but we cannot evade the consequences of evading reality'
August 29, 2025 - - Latest News -
Australians fear the loss of independence as vision health concerns rise
August 29, 2025 - - Latest News -
Coalition turns debate on cheaper medicines Bill to HTA reform delays
August 27, 2025 - - Latest News